In the RATIFY trial, adult AML patients <60 years old were tested for FLT3 mutations, and if found positive were randomised to adding placebo or the FLT3 inhibitor midostaurin to standard chemotherapy during the entire treatment course (induction with daunorubicin+ Ara-C, consolidation with Ara-C and maintenance with midostaurin/placebo). The gene discussed is FLT3; the disease is acute myeloid leukemia.